Generalized vitiligo (GV) is characterized by autoimmune destruction of melanocytes by skin-homing cytotoxic T-cells (CTLs) that target melanocyte autoantigens. Two recent genomewide association studies (GWAS) of GV in European-derived whites (EUR) have demonstrated genetic association with , encoding granzyme B, a marker of activated CTLs that mediates target-cell apoptosis, as well as autoantigen activation and consequent initiation and propagation of autoimmunity. Here, we describe detailed genetic analyses of the region of chromosome 14q12 to identify genetic variation potentially causal for GV, implicating two non-synonymous SNPs in strong linkage disequilibrium that comprise part of a common multi-variant high-risk haplotype, rs8192917-C— rs11539752-C (55R-94A). To identify possible uncommon deleterious variants that might “hitchhike” on the high-risk haplotype, we then carried out “next-generation” DNA re-sequencing of in 114 EUR GV patients. Overall, our findings support a direct causal role for the rs8192917-C—rs11539752-C haplotype (55R-94A) in the pathogenesis of GV.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634907PMC
http://dx.doi.org/10.1038/jid.2013.5DOI Listing

Publication Analysis

Top Keywords

generalized vitiligo
8
encoding granzyme
8
high-risk haplotype
8
risk generalized
4
vitiligo associated
4
associated common
4
common 55r-94a-247h
4
55r-94a-247h variant
4
haplotype
4
variant haplotype
4

Similar Publications

Vitiligo-like hypopigmentation induced by immune checkpoint inhibitors (ICIs) has been largely associated with improved survival outcomes in metastatic melanoma. However, its development during adjuvant ICI therapy and its role as a prognostic factor in this setting remain unclear. We aimed to describe ICI-induced vitiligo in a cohort of patients with resected stage III melanoma treated with adjuvant ICI and to identify differences in progression-free survival (PFS) and distant metastasis-free survival (DMFS) between those who developed vitiligo and those who did not.

View Article and Find Full Text PDF

Objectives: Skin conditions carry a substantial psychological burden but support for patients is limited. Digital technology could support patient self-management; we found preliminary evidence for the effectiveness and acceptability of digital psychological interventions for adults living with skin conditions. We have, therefore, developed a complex digital intervention called MiDerm with patients.

View Article and Find Full Text PDF

Biological drugs are extensively used to treat various inflammatory diseases, including psoriasis, atopic dermatitis (AD), and rheumatoid arthritis. While generally effective and safe, these therapies have been increasingly associated with secondary development of vitiligo, especially with anti-TNF α and anti-IL17 drugs. Dupilumab, an IL-4 receptor alpha antagonist used in moderate to severe AD, rarely induces vitiligo.

View Article and Find Full Text PDF

Vitiligo is a skin disease that affects all ethnicities and genders and is characterized by the loss of pigment essentially due to the selective loss of melanocytes. Although it is generally considered a systemic disease associated with polymorphisms in genes involved in the immune response, vitiligo is also considered an oxidative imbalance-associated disease. It represents a multifactorial pathology in which some genetic predisposition and epigenetic factors coupled with some critical biochemical and molecular pathways could play a pivotal role.

View Article and Find Full Text PDF

Detection of Vitiligo Through Machine Learning and Computer-Aided Techniques: A Systematic Review.

Biomed Res Int

December 2024

Department of Biomedical Engineering, Ziauddin University, Faculty of Engineering, Science, Technology and Management (ZUFESTM), Karachi, Pakistan.

Vitiligo is a chronic skin damage disease, triggered by differential melanocyte death. Vitiligo (0.5%-1% of the population) is one of the most severe skin conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!